CN112969799A - 2′fana修饰的foxp3反义寡核苷酸及其使用方法 - Google Patents

2′fana修饰的foxp3反义寡核苷酸及其使用方法 Download PDF

Info

Publication number
CN112969799A
CN112969799A CN201980067095.XA CN201980067095A CN112969799A CN 112969799 A CN112969799 A CN 112969799A CN 201980067095 A CN201980067095 A CN 201980067095A CN 112969799 A CN112969799 A CN 112969799A
Authority
CN
China
Prior art keywords
aon
fana
seq
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980067095.XA
Other languages
English (en)
Chinese (zh)
Inventor
V·艾西瓦亚
W·W·汉考克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aum Life Technologies
Children's Hospital of Philadelphia
Original Assignee
Aum Life Technologies
Children's Hospital of Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aum Life Technologies, Children's Hospital of Philadelphia filed Critical Aum Life Technologies
Publication of CN112969799A publication Critical patent/CN112969799A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980067095.XA 2018-09-26 2019-09-25 2′fana修饰的foxp3反义寡核苷酸及其使用方法 Pending CN112969799A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862737061P 2018-09-26 2018-09-26
US62/737,061 2018-09-26
US201862739001P 2018-09-28 2018-09-28
US62/739,001 2018-09-28
PCT/US2019/053033 WO2020069044A1 (en) 2018-09-26 2019-09-25 2' fana modified foxp3 antisense oligonucleotides and methods of use thereof

Publications (1)

Publication Number Publication Date
CN112969799A true CN112969799A (zh) 2021-06-15

Family

ID=69953290

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980067095.XA Pending CN112969799A (zh) 2018-09-26 2019-09-25 2′fana修饰的foxp3反义寡核苷酸及其使用方法

Country Status (7)

Country Link
US (1) US20210340536A1 (enExample)
EP (1) EP3856919A4 (enExample)
JP (1) JP2022502062A (enExample)
CN (1) CN112969799A (enExample)
AU (1) AU2019347849B2 (enExample)
CA (1) CA3112809A1 (enExample)
WO (1) WO2020069044A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115176008A (zh) * 2019-12-30 2022-10-11 瑟卡尔纳制药有限公司 用于抑制FoxP3表达的修饰反义寡核苷酸

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202028222A (zh) * 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
WO2023235838A2 (en) * 2022-06-02 2023-12-07 Skyhawk Therapeutics, Inc. Rna-targeting splicing modifiers for treatment of foxp3-associated conditions and diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1330513A (zh) * 1999-04-06 2002-01-09 东卡罗来纳大学 低腺苷反义寡核苷酸、组合物、试剂盒及与支气管紧缩、肺炎、过敏及表面活性剂缺失相关的通气途径疾病的治疗方法
WO2010048673A1 (en) * 2008-10-30 2010-05-06 Murdoch Childrens Research Institute Modulation of cellular differentiation and uses therefor
CN102099474A (zh) * 2008-05-15 2011-06-15 托皮根药品公司 用于治疗炎症和赘生性细胞增殖的寡核苷酸
CN102341498A (zh) * 2008-12-04 2012-02-01 欧科库尔纳有限责任公司 通过抑制血管内皮生长因子(vegf)的天然反义转录子治疗vegf相关的疾病

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE346918T1 (de) * 1998-06-19 2006-12-15 Univ Mcgill Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
CA2419563C (en) * 2000-09-06 2018-03-20 Mcgill University Chimeric antisense of arabinofuranose analogue and deoxyribose nucleotides
DK1470144T3 (da) * 2002-02-01 2009-04-06 Univ Mcgill Oligonukleotider omfattende alternerende segmenter og anvendelser deraf
CA2652539A1 (en) * 2006-05-19 2007-11-29 Topigen Pharmaceuticals Inc. Oligonucleotides affecting expression of phosphodiesterases
WO2008066784A2 (en) * 2006-11-27 2008-06-05 Ludwig Institute For Cancer Research Expression of foxp3 by cancer cells
US20100310635A1 (en) * 2007-04-25 2010-12-09 Engin Ozkaynak Compositions and Methods for Regulating T-Cell Activity
KR20160027968A (ko) * 2013-06-07 2016-03-10 라나 테라퓨틱스, 인크. Ｆｏｘｐ3 발현을 조절하기 위한 조성물 및 방법
WO2017181026A1 (en) * 2016-04-15 2017-10-19 Translate Bio Ma, Inc. Selective modulation of foxp3 expression
US20200030361A1 (en) * 2016-09-23 2020-01-30 City Of Hope Oligonucleotides containing 2'-deoxy-2'fluoro-beta-d-arabinose nucleic acid (2'-fana) for treatment and diagnosis of retroviral diseases
FR3058061A1 (fr) * 2016-10-27 2018-05-04 Selexel Nouvelle utilisation d'oligonucleotides double brin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1330513A (zh) * 1999-04-06 2002-01-09 东卡罗来纳大学 低腺苷反义寡核苷酸、组合物、试剂盒及与支气管紧缩、肺炎、过敏及表面活性剂缺失相关的通气途径疾病的治疗方法
CN102099474A (zh) * 2008-05-15 2011-06-15 托皮根药品公司 用于治疗炎症和赘生性细胞增殖的寡核苷酸
WO2010048673A1 (en) * 2008-10-30 2010-05-06 Murdoch Childrens Research Institute Modulation of cellular differentiation and uses therefor
CN102341498A (zh) * 2008-12-04 2012-02-01 欧科库尔纳有限责任公司 通过抑制血管内皮生长因子(vegf)的天然反义转录子治疗vegf相关的疾病

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHARLES SINCLAIR ET AL: "Abstract 5561: High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T-cells and produce antitumor effects in syngeneic tumor models", 《CANCER RES》, vol. 78, 1 July 2018 (2018-07-01), XP055946958 *
KYUNG-LYUM MIN ET AL: "Oligonucleotides Comprised of Alternating 2\'-Deoxy-2\'-fluoro-β-D-arabinonucleosides and D-2\'-deoxyribonucleosides(2\'F-ANA/DNA ‘Altimers’) Induce Efficient RNA Cleavage Mediated by RNase H", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 12, 31 October 2002 (2002-10-31), pages 2651 *
刘冰 等: "FOXP3基因在人类变应性鼻炎中的表达", 《实用医学杂志》, vol. 26, no. 22, 25 November 2010 (2010-11-25), pages 4065 - 4067 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115176008A (zh) * 2019-12-30 2022-10-11 瑟卡尔纳制药有限公司 用于抑制FoxP3表达的修饰反义寡核苷酸
CN115176008B (zh) * 2019-12-30 2026-01-30 瑟卡尔纳制药有限公司 用于抑制FoxP3表达的修饰反义寡核苷酸
US12680098B2 (en) 2019-12-30 2026-07-14 Secarna Pharmaceuticals Gmbh & Co. Kg Modified antisense oligonucleotide for inhibition of FoxP3 expression

Also Published As

Publication number Publication date
AU2019347849B2 (en) 2025-08-28
CA3112809A1 (en) 2020-04-02
EP3856919A4 (en) 2023-08-02
EP3856919A1 (en) 2021-08-04
WO2020069044A1 (en) 2020-04-02
AU2019347849A1 (en) 2021-05-20
JP2022502062A (ja) 2022-01-11
US20210340536A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
CN108025018B (zh) 用于治疗癌症的pd-1拮抗剂和cpg-c型寡核苷酸的组合产品
AU2015335029B2 (en) Combination
JP6991857B2 (ja) Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
WO2007127624A1 (en) Reducing cancer cell invasion using an inhibitor of toll like receptor signaling
JP2025169317A (ja) がんの処置のための方法および組成物
AU2019347849B2 (en) 2'FANA modified Foxp3 antisense oligonucleotides and methods of use thereof
JP2010525811A (ja) 腫瘍増殖阻害化合物及びそれらの使用方法
CN112996504A (zh) 通过抑制泛素缀合酶e2 k(ube2k)治疗癌症的方法
US20220220485A1 (en) PD-L1 antisense oligonucleotides for use in tumor treatment
EP3515486A1 (en) Methods of treating tim-3 elevation
WO2025029625A9 (en) Compositions and methods for programmed death ligand receptor (pd-l1) expression
HK40050192A (en) 2' fana modified foxp3 antisense oligonucleotides and methods of use thereof
US20250367289A1 (en) Dosage regimen for a combination therapy consisting oftcr-engineered t-cells in combination with a pd-1 axis binding antagonist
JP7099678B2 (ja) 活性成分としてｌｒｉｔ２阻害剤を含む、がんを予防又は治療するための医薬組成物
US20230340127A1 (en) Methods and compositions for cancer treatment by inhibition of fbxo44
KR20260035590A (ko) Nk세포의 nkg2a 억제제 및 ilt2 억제제를 포함하는 면역항암치료의 효능 증진용 조성물 및 면역항암치료의 효능 증진 방법
WO2025134119A1 (en) Reprogrammed dysfunctional natural killer cells and uses thereof
HK40054961A (en) Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)
HK1238287A1 (en) Combination

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050192

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210615

WD01 Invention patent application deemed withdrawn after publication